Table 1 Characteristics of study cohorts
Group | Discovery cohort | Validation cohort | ||
|---|---|---|---|---|
Chemoresistant OS (n=6) | Control (n=6) | Chemoresistant OS (n=35) | Control (n=35) | |
Age (years) | ||||
Mean±SD | 9.6±4.2 | 9.6±4.2 | 9.9±4.9 | 10.1±5.2 |
Range | 7–14 | 7–14 | 6–16 | 6–16 |
Gender n (%) | ||||
Male | 3 (50) | 3 (50) | 21 (60) | 23 (66) |
Female | 3 (50) | 3 (50) | 14 (40) | 12 (34) |
Tumor stage n (%) | ||||
Stage IIA | 2 (33) | 2 (33) | 8 (23) | 7 (20) |
Stage IIB | 2 (33) | 2 (33) | 13 (37) | 13 (37) |
Stage III | 2 (33) | 2 (33) | 14 (40) | 15 (43) |
Body mass index (kg/m2) | 17.5±4.0 | 18.2±4.1 | 17.7±3.8 | 18.3±4.0 |
Tumor necrosis (%) | 94.1±2.8 | 70.8±9.2* | 93.5±3.6 | 73.6±12.2* |